ondansetron has been researched along with Ischemic Attack, Transient in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murozono, M | 1 |
| Miyashita, R | 1 |
| Takeda, A | 1 |
| Ynagita, K | 1 |
| Sato, E | 1 |
| Ogiwara, Y | 1 |
1 other study available for ondansetron and Ischemic Attack, Transient
| Article | Year |
|---|---|
Co-administration of Cyclosporin A and Ondansetron decreases transient local cerebral ischemic injury in the mouse.
Topics: Animals; Cerebrovascular Circulation; Cyclosporine; Disease Models, Animal; Drug Therapy, Combinatio | 2017 |